Project Grant R34CA297281
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $682K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- The University of Michigan was awarded a $2,284,054 Project Grant by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program. The 4-year grant, which began on September 1, 2025, will support research to transform molecular cancer screening through the development of stimulated Raman histology and deep neural networks. The project aims to improve access to molecular cancer testing by creating innovative diagnostic tools and methods...
- The University of Michigan has been awarded a $568,151 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a real-time functional imaging platform for accurate diagnosis and prognosis of prostate cancer. The project aims to leverage photoacoustic imaging and biocompatible hydrogel nanoparticle probes to quantitatively assess prostate gland microarchitecture and tumor microenvironment as imaging biomarkers for improved prostate...
- This $1,248,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support the "RARE-CANCER COMMONS: A HUB FOR ACCELERATING INDIVIDUALIZED RARE CANCER THERAPY THROUGH INTEGRATION OF SINGLE-CELL AND CLINICAL GENOMICS DATA" research initiative at the University of Michigan. The project, running from November 1, 2024 to October 31, 2027, will leverage the University's extensive research capabilities to...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $319,505 to the Regents of the University of Michigan to build nationwide investigator capacity in methods for adapting and personalizing cancer control interventions. The project aims to address the growing demand for new methodological skills in developing adaptive interventions, which are evidence-based protocols that guide how individual information can be used to deliver...
- The National Cancer Institute (NCI) awarded a $386,866 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Regents of the University of Michigan to develop individualized estimates of treatment benefit from hormone therapy for men with prostate cancer. The project aims to integrate models for other-cause mortality risk, distant metastases, and prostate cancer-specific mortality to provide personalized estimates of treatment outcomes, and to develop a web...
- The National Cancer Institute (NCI) awarded a $361,695 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Oklahoma Health Sciences Center (OUHSC) for the period of September 1, 2025 to August 31, 2029. The grant aims to: 1) Leverage novel mHealth applications to boost enrollment in NCI-sponsored clinical trials, 2) Promote representative clinical trial enrollment from the local catchment area population, 3) Expand Veteran access to NCI trials, and 4)...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $1,338,648 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Pittsburgh. The grant will fund a "Hybrid Type I Cluster Randomized Effectiveness-Implementation Trial of CARES" to address clinically significant levels of depression, pain, and fatigue experienced by over 18 million Americans living with cancer. The project aims to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $509,246 to the Regents of the University of Michigan to conduct research on early drivers of prostate cancer lineage plasticity. The project aims to identify key transcriptional regulators that repress androgen receptor signaling and promote alternate differentiation programs in prostate cancer, with the goal of preventing lineage plasticity and disease progression. By...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $316,873 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to develop and evaluate a Spanish-language mobile health (mHealth) smoking cessation app. The goal is to extend the reach of the team's previously validated printed smoking cessation intervention for Hispanic/Latinx smokers, a population disproportionately impacted by smoking-related...
- This $1,844,306 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the University of Michigan to cotarget the NSD1/2 paralogs in androgen receptor (AR)-driven castration-resistant prostate cancer. The research aims to transform healthcare for military service members, veterans, and the public by developing innovative medical solutions to address critical health challenges. The project will run...